Literature DB >> 24623426

Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses.

Julia Weinelt1, Stuart J D Neil.   

Abstract

UNLABELLED: The mammalian antiviral membrane protein tetherin (BST2/CD317) can be expressed as two isoforms derived from differential translational initiation. The shorter isoform of the human protein (S-tetherin) lacks the first 12 amino acids of the longer (L-tetherin) cytoplasmic tail, which includes a tyrosine motif that acts as both an endocytic recycling signal and a determinant of virus-induced NF-κB activation. S-tetherin is also reported to be less sensitive to the prototypic viral antagonist human immunodeficiency virus type 1 (HIV-1) Vpu. Here we analyzed the relative sensitivities of L- and S-tetherins to primate lentiviral countermeasures. We show that the reduced sensitivity of S-tetherin to HIV-1 Vpu is a feature of all group M proteins, including those of transmitted founder viruses, primarily because it cannot be targeted for endosomal degradation owing to the truncation of its cytoplasmic tail. In contrast, both isoforms of the human and rhesus macaque tetherins display the same sensitivity to nondegradative lentiviral countermeasures of HIV-2 and SIVmac, respectively. Surprisingly, however, the Vpu proteins encoded by simian immunodeficiency viruses (SIVs) of African guenons, as well as that from recently isolated highly pathogenic HIV-1 group N, do not discriminate between tetherin isoforms. Together, these data suggest that the group M HIV-1 Vpu primarily adapted to target L-tetherin upon zoonotic transmission from chimpanzees, and further, we speculate that functions specifically associated with this isoform, such as proinflammatory signaling, play key roles in human tetherin's antiviral function in vivo. IMPORTANCE: The ability of HIV-1 and related viruses to counteract a host antiviral protein, tetherin, is strictly maintained. The adaptation of the HIV-1 Vpu protein to counteract human tetherin is thought to have been one of the key events in the establishment of the HIV/AIDS pandemic. Recent evidence shows that tetherin is expressed as two isoforms and that Vpu preferentially targets the longer form. Here we show that unlike other virus-encoded countermeasures, such as those from primate viruses related to HIV-1, the enhanced ability to counteract the long tetherin isoform is conserved among HIV-1 strains that make up the majority of the human pandemic. This correlates with the ability of Vpu to induce long tetherin degradation. We speculate that functions associated with the human version of this isoform, such as an inflammatory signaling capacity, selected for Vpu's enhanced targeting of long tetherin during its adaptation to humans.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24623426      PMCID: PMC4019096          DOI: 10.1128/JVI.03818-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Authors:  Raphaël Vigan; Stuart J D Neil
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release.

Authors:  Fengwen Zhang; Wilmina N Landford; Melinda Ng; Matthew W McNatt; Paul D Bieniasz; Theodora Hatziioannou
Journal:  PLoS Pathog       Date:  2011-05-19       Impact factor: 6.823

3.  Tetherin restricts productive HIV-1 cell-to-cell transmission.

Authors:  Nicoletta Casartelli; Marion Sourisseau; Jerome Feldmann; Florence Guivel-Benhassine; Adeline Mallet; Anne-Geneviève Marcelin; John Guatelli; Olivier Schwartz
Journal:  PLoS Pathog       Date:  2010-06-17       Impact factor: 6.823

4.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

Authors:  Daniel Sauter; Michael Schindler; Anke Specht; Wilmina N Landford; Jan Münch; Kyeong-Ae Kim; Jörg Votteler; Ulrich Schubert; Frederic Bibollet-Ruche; Brandon F Keele; Jun Takehisa; Yudelca Ogando; Christina Ochsenbauer; John C Kappes; Ahidjo Ayouba; Martine Peeters; Gerald H Learn; George Shaw; Paul M Sharp; Paul Bieniasz; Beatrice H Hahn; Theodora Hatziioannou; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2009-11-19       Impact factor: 21.023

5.  Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.

Authors:  Efrem S Lim; Harmit S Malik; Michael Emerman
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

6.  Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Authors:  Bin Jia; Ruth Serra-Moreno; William Neidermyer; Andrew Rahmberg; John Mackey; Ismael Ben Fofana; Welkin E Johnson; Susan Westmoreland; David T Evans
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

7.  Nef proteins from simian immunodeficiency viruses are tetherin antagonists.

Authors:  Fengwen Zhang; Sam J Wilson; Wilmina C Landford; Beatriz Virgen; Devon Gregory; Marc C Johnson; Jan Munch; Frank Kirchhoff; Paul D Bieniasz; Theodora Hatziioannou
Journal:  Cell Host Microbe       Date:  2009-06-04       Impact factor: 21.023

8.  Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.

Authors:  Ravindra K Gupta; Petra Mlcochova; Annegret Pelchen-Matthews; Sarah J Petit; Giada Mattiuzzo; Deenan Pillay; Yasuhiro Takeuchi; Mark Marsh; Greg J Towers
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-28       Impact factor: 11.205

9.  Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals.

Authors:  Suzanne Pickering; Stephane Hué; Eun-Young Kim; Susheel Reddy; Steven M Wolinsky; Stuart J D Neil
Journal:  PLoS Pathog       Date:  2014-01-23       Impact factor: 6.823

10.  Tetherin restricts herpes simplex virus 1 and is antagonized by glycoprotein M.

Authors:  Caroline Blondeau; Annegret Pelchen-Matthews; Petra Mlcochova; Mark Marsh; Richard S B Milne; Greg J Towers
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

View more
  18 in total

1.  Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.

Authors:  Katharina Mack; Kathrin Starz; Daniel Sauter; Simon Langer; Frederic Bibollet-Ruche; Gerald H Learn; Christina M Stürzel; Marie Leoz; Jean-Christophe Plantier; Matthias Geyer; Beatrice H Hahn; Frank Kirchhoff
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

2.  Mechanism of Tetherin Inhibition of Alphavirus Release.

Authors:  Judy J Wan; Yaw Shin Ooi; Margaret Kielian
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

3.  Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.

Authors:  Mariana G Bego; Lijun Cong; Katharina Mack; Frank Kirchhoff; Éric A Cohen
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

4.  BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Authors:  Jonathan Richard; Jérémie Prévost; Benjamin von Bredow; Shilei Ding; Nathalie Brassard; Halima Medjahed; Mathieu Coutu; Bruno Melillo; Frédéric Bibollet-Ruche; Beatrice H Hahn; Daniel E Kaufmann; Amos B Smith; Joseph Sodroski; Daniel Sauter; Frank Kirchhoff; Katrina Gee; Stuart J Neil; David T Evans; Andrés Finzi
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

5.  Tetherin Antagonism by HIV-1 Group M Nef Proteins.

Authors:  Juan F Arias; Marta Colomer-Lluch; Benjamin von Bredow; Justin M Greene; Julie MacDonald; David H O'Connor; Ruth Serra-Moreno; David T Evans
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

6.  The sheep tetherin paralog oBST2B blocks envelope glycoprotein incorporation into nascent retroviral virions.

Authors:  Lita Murphy; Mariana Varela; Sophie Desloire; Najate Ftaich; Claudio Murgia; Matthew Golder; Stuart Neil; Thomas E Spencer; Sarah K Wootton; Dimitri Lavillette; Christophe Terzian; Massimo Palmarini; Frédérick Arnaud
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

7.  Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells.

Authors:  Mariana G Bego; Édouard Côté; Nick Aschman; Johanne Mercier; Winfried Weissenhorn; Éric A Cohen
Journal:  PLoS Pathog       Date:  2015-07-14       Impact factor: 6.823

8.  Antiviral potency and functional analysis of tetherin orthologues encoded by horse and donkey.

Authors:  Xin Yin; Miaomiao Guo; Qinyong Gu; Xingliang Wu; Ping Wei; Xiaojun Wang
Journal:  Virol J       Date:  2014-08-27       Impact factor: 4.099

9.  Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors.

Authors:  Tonya Kueck; Toshana L Foster; Julia Weinelt; Jonathan C Sumner; Suzanne Pickering; Stuart J D Neil
Journal:  PLoS Pathog       Date:  2015-08-28       Impact factor: 6.823

10.  Retroviral retention activates a Syk-dependent HemITAM in human tetherin.

Authors:  Rui Pedro Galão; Suzanne Pickering; Rachel Curnock; Stuart J D Neil
Journal:  Cell Host Microbe       Date:  2014-09-10       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.